Table 1.
Patient Characteristics and Univariable Analyses of Recurrence
| Characteristic | No. (%) | 5-Year CIR (95% CI), % | P* |
|---|---|---|---|
| All patients | 1,120 | 18.2 (16.0 to 20.8) | |
| Age, years | .45 | ||
| ≤ 65 | 404 (36) | 20.2 (16.4 to 24.9) | |
| > 65 | 716 (64) | 17.1 (14.4 to 20.3) | |
| Sex | .038 | ||
| Female | 696 (62) | 16.5 (13.7 to 19.7) | |
| Male | 434 (39) | 21.1 (17.4 to 25.7) | |
| Smoking history | .243 | ||
| Never | 197 (18) | 16.0 (11.3 to 22.6) | |
| Ever | 923 (82) | 18.7 (16.2 to 21.6) | |
| Surgical procedure† | < .001 | ||
| Lobectomy | 807 (72) | 15.5 (13.0 to 18.4) | |
| Sublobar resection | 313 (28) | 25.1 (20.5 to 30.7) | |
| T factor | < .001 | ||
| T1a | 632 (56) | 14.0 (11.4 to 17.2) | |
| T1b | 215 (19) | 17.2 (12.5 to 23.8) | |
| T2a | 273 (24) | 29.0 (23.7 to 35.5) | |
| Pathologic stage | < .001 | ||
| IA | 847 (76) | 14.8 (12.5 to 17.6) | |
| IB | 273 (24) | 29.0 (23.7 to 35.5) | |
| Predominant histologic subtype | < .001 | ||
| Adenocarcinoma in situ | 2 (0.2) | NA | |
| Minimally invasive adenocarcinoma | 32 (3) | 0 | |
| Lepidic | 137 (12) | 6.8 (3.5 to 13.4) | |
| Acinar | 453 (40) | 16.6 (13.3 to 20.7) | |
| Papillary | 244 (22) | 16.6 (12.2 to 22.7) | |
| Micropapillary | 68 (6) | 40.9 (29.9 to 56.0) | |
| Solid | 146 (13) | 29.1 (22.3 to 37.9) | |
| Invasive mucinous | 40 (4) | 19.8 (10.1 to 39.1) | |
| Colloid | 9 (0.8) | NA | |
| Architectural grade | < .001 | ||
| Low | 171 (15) | 5.5 (2.8 to 10.8) | |
| Intermediate | 686 (61) | 16.6 (13.9 to 19.9) | |
| High | 263 (23) | 30.7 (25.3 to 37.2) | |
| Lymphatic invasion | < .001 | ||
| Absent | 751 (67) | 11.6 (9.4 to 14.4) | |
| Present | 369 (33) | 31.6 (27.0 to 37.0) | |
| Vascular invasion | < .001 | ||
| Absent | 862 (77) | 13.5 (11.2 to 16.2) | |
| Present | 258 (23) | 33.8 (28.2 to 40.5) | |
| Pleural invasion | < .001 | ||
| Absent | 966 (86) | 16.2 (13.9 to 18.9) | |
| Present | 154 (14) | 30.9 (24.0 to 39.8) | |
| Mutation | .11 | ||
| Wild | 326 (29) | 20.6 (16.3 to 26.0) | |
| EGFR | 96 (9) | 12.8 (6.6 to 24.8) | |
| KRAS | 133 (12) | 16.2 (10.4 to 25.0) | |
| Adjuvant chemotherapy (stage IB) | |||
| No | 249 (90) | 29.6 (24.1 to 36.4) | .15 |
| Yes | 24 (10) | 21.5 (8.7 to 53.4) |
Abbreviations: CIR, cumulative incidence of recurrence; EGFR, epidermal growth factor receptor; NA, not applicable.
*
Significant P values (< .05) are shown in bold type.
†
Lobectomy: pneumonectomy, bilobectomy, or lobectomy; sublobar resection: segmentectomy or wedge resection.